GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » EV-to-FCF

Immuron (STU:ANWA) EV-to-FCF : -1.09 (As of May. 20, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Immuron EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Immuron's Enterprise Value is €2.41 Mil. Immuron's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.22 Mil. Therefore, Immuron's EV-to-FCF for today is -1.09.

The historical rank and industry rank for Immuron's EV-to-FCF or its related term are showing as below:

STU:ANWA' s EV-to-FCF Range Over the Past 10 Years
Min: -27   Med: -4.37   Max: 1.67
Current: -0.47

During the past 9 years, the highest EV-to-FCF of Immuron was 1.67. The lowest was -27.00. And the median was -4.37.

STU:ANWA's EV-to-FCF is ranked worse than
100% of 378 companies
in the Biotechnology industry
Industry Median: 8.59 vs STU:ANWA: -0.47

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-20), Immuron's stock price is €2.18. Immuron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.419. Therefore, Immuron's PE Ratio for today is At Loss.


Immuron EV-to-FCF Historical Data

The historical data trend for Immuron's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron EV-to-FCF Chart

Immuron Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only -8.03 -13.71 -2.77 1.24 0.66

Immuron Semi-Annual Data
Jun15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1.24 - 0.66 -

Competitive Comparison of Immuron's EV-to-FCF

For the Biotechnology subindustry, Immuron's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuron's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Immuron's EV-to-FCF falls into.



Immuron EV-to-FCF Calculation

Immuron's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=2.414/-2.224
=-1.09

Immuron's current Enterprise Value is €2.41 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Immuron's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-2.22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immuron  (STU:ANWA) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Immuron's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.18/-0.419
=At Loss

Immuron's share price for today is €2.18.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Immuron's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.419.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Immuron EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Immuron's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuron (STU:ANWA) Business Description

Traded in Other Exchanges
Address
Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130
Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (STU:ANWA) Headlines

No Headlines